CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has mutually agreed to terminate its licence agreement with US-based BioFactura Inc for the commercialisation of BFI-751, a proposed biosimilar of ustekinumab (Stelara).
The company said the decision followed a strategic review and aligns with CuraTeQ’s portfolio prioritisation efforts. The agreement, executed in July 2023, envisaged the commercialisation of the biosimilar in regulated markets.
Under the arrangement, BioFactura was entitled to licence fees linked to development and commercial milestones, while CuraTeQ held global manufacturing rights under a profit-sharing structure.
Aurobindo Pharma clarified that the termination, effective December 27, 2025, was reached by mutual consent and is not expected to have any material impact on its broader biosimilars strategy.
The company also said that BioFactura is not related to the promoter or promoter group and that the transaction does not fall under related-party dealings.
The move reflects CuraTeQ’s continued focus on optimising its biosimilars pipeline and reallocating resources towards priority programmes. Aurobindo Pharma reiterated that the decision does not affect its long-term commitment to the biosimilars segment or its overall growth plans in the space.
Shares of Aurobindo Pharma Ltd closed at ₹1,208.30 on Friday, down 0.26% on the NSE.
